Learning Objectives
Upon completion of this activity, participants should be able to:
- Review recent data regarding the metabolic side effects associated with specific antiretroviral agents
- Describe data on potential therapeutic interventions for metabolic complications and lipodystrophy in HIV-infected patients
- Discuss antiretroviral treatment strategies for preventing and managing metabolic complications and lipodystrophy in HIV-infected patients
Topics covered include:
- Overview
- Effects of Stavudine Switch on Peripheral Lipoatrophy, Lipids, and Lipid-Associated Factors
- Effects of Switching Stavudine to Tenofovir or Abacavir on Facial Lipoatrophy
- Predictors of Lipoatrophy
- Effects of Uridine Supplementation on Lipoatrophy in HIV-Infected Patients
- Effects of Pravastatin on Dyslipidemia and Peripheral Lipoatrophy in HIV-Infected Patients
- Efficacy and Safety of Extended-Release Niacin in HIV-Infected Patients With Dyslipidemia
- Effects of Protease Inhibitors on Insulin Resistance in Healthy Volunteers
- Relationship Between Hepatic Steatosis and Insulin Resistance in HIV-Infected Patients